Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on Foxp3 As Target

Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on Foxp3 As Target Publisher Pubmed

Mousaviniri N¹ ; Naseroleslami M² ; Hadjati J³

Source: Human Vaccines and Immunotherapeutics Published:2019

Abstract

Anti- tumor vaccination elicits imperfect immune responses against tumor cells; that is related to the presence of suppressive obstacles in the tumor microenvironment. The main members of suppressive milieu of tumor are heteroogenous groups of immune cells in which regulatory T cell is a substantial component. Tregs express different immunomodulatory molecules such as FoxP3. Transcription factor, FoxP3, is a specific intracellular marker of Treg and crucial for Treg development. Therefore it is an attractive target for cancer treatment. This article reviews some recent anti-Treg vaccine focusing on FoxP3 to ameliorate anti-tumor immune responses. Among them, fusion vaccine of FoxP3-Fc(IgG) recombinant DNA vaccine and its accordant protein vaccine represents effective results. © 2019, © 2019 Taylor & Francis Group, LLC.

Related Docs

View other Related Docs

1. Improved Anti-Treg Vaccination Targeting Foxp3 Efficiently Decreases Regulatory T Cells in Mice, Journal of Immunotherapy (2016)

2. Prophylactic Dna Vaccine Targeting Foxp3+ Regulatory T Cells Depletes Myeloid-Derived Suppressor Cells and Improves Anti-Melanoma Immune Responses in a Murine Model, Cancer Immunology# Immunotherapy (2018)

3. Construction and Production of Foxp3- Fc (Igg) Dna Vaccine/Fusion Protein, Avicenna Journal of Medical Biotechnology (2016)

Experts (# of related papers)

View all Related Experts

Jamshid Hadjati (4)

Nima Rezaei (3)

Style	Citing Format
MLA	Mousaviniri N, Naseroleslami M, Hadjati J. "Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on Foxp3 As Target." Human Vaccines and Immunotherapeutics, vol. 15, no. 3, 2019, pp. 620-624.
APA	Mousaviniri N, Naseroleslami M, Hadjati J (2019). Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on Foxp3 As Target. Human Vaccines and Immunotherapeutics, 15(3), 620-624.
Chicago	Mousaviniri N, Naseroleslami M, Hadjati J. "Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on Foxp3 As Target." Human Vaccines and Immunotherapeutics 15, no. 3 (2019): 620-624.
Harvard	Mousaviniri N, Naseroleslami M, Hadjati J (2019) 'Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on Foxp3 As Target', Human Vaccines and Immunotherapeutics, 15(3), pp. 620-624.
Vancouver	Mousaviniri N, Naseroleslami M, Hadjati J. Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on Foxp3 As Target. Human Vaccines and Immunotherapeutics. 2019;15(3):620-624.
BibTex	@article{ author = {Mousaviniri N and Naseroleslami M and Hadjati J}, title = {Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on Foxp3 As Target}, journal = {Human Vaccines and Immunotherapeutics}, volume = {15}, number = {3}, pages = {620-624}, year = {2019} }
RIS	TY - JOUR AU - Mousaviniri N AU - Naseroleslami M AU - Hadjati J TI - Anti-Regulatory T Cell Vaccines in Immunotherapy: Focusing on Foxp3 As Target JO - Human Vaccines and Immunotherapeutics VL - 15 IS - 3 SP - 620 EP - 624 PY - 2019 ER -

Science Communicator Platform

Authors

Abstract